Viking Therapeutics, Inc. (VKTX) News
Filter VKTX News Items
VKTX News Results
|Loading, please wait...|
VKTX News Highlights
- For VKTX, its 30 day story count is now at 8.
- Over the past 16 days, the trend for VKTX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about VKTX are LIAN, ACT and SAFE.
Latest VKTX News From Around the Web
Below are the latest news stories about Viking Therapeutics Inc that investors may wish to consider to help them evaluate VKTX as an investment opportunity.
In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $10.00. The company's shares closed last Thursday at $4.05, close to its 52-week low of $3.22. According to TipRanks.com, Rahman 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -34.2% and a 11.5% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Vertex Pharmaceuticals, and Galmed Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viking Therapeutics with a $19.
The stock market is giving investors some real healthcare bargains right now. Patrick Bafuma (Intercept Pharma): I will freely admit that Intercept Pharma has been a dog through the years, down a maddening 87% over the last five years. A significant portion of Intercept's drop was also due to a complete response letter in June 2020 for the treatment of non-alcoholic steatohepatitis (NASH).
Joining me today is Brian Lian, Viking's president and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that comments made during this conference call today, February 9, 2022, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, time lines, and milestones.
Viking Therapeutics press release (NASDAQ:VKTX): Q4 GAAP EPS of -$0.16 beats by $0.03....
Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2021, and provided an update on its clinical pipeline and other corporate developments.
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the SVB Leerink 11th Annual Global Healthcare Conference. The conference, which will take place February 14-18, 2022, is being conducted with a virtual format.
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2021 on February 9, 2022
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the fourth quarter and year-end 2021, after the market close on Wednesday, February 9, 2022.
Viking (VKTX) phase Ib study on VK0214 in patients with X-ALD put on hold by the FDA.
Viking Therapeutics (VKTX) announces that its Phase 1b clinical trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD) has been placed on clinical hold by the FDA.The
The clinical trial has been halted by the FDA for now, pending the submittal of a preclinical study.